AO-252

· A2A Pharmaceuticals Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AO-252, covering 2025-10-01 to 2025-10-01. Get the full timeline:

Most recent: Clinical Trial Update: A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases [Phase 1]

See pricing